Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage (Q36256080)

13 August 2017

Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage (English)

1 reference

13 August 2017

David L Brody

1

1 reference

13 August 2017

Venkatesh Aiyagari

series ordinal

2

1 reference

13 August 2017

Angela M Shackleford

series ordinal

3

1 reference

13 August 2017

Michael N Diringer

series ordinal

4

1 reference

13 August 2017

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

2

1 reference

13 August 2017

3

1 reference

13 August 2017

263-267

1 reference

13 August 2017

Ongoing NovoSeven trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2535929

Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2535929

The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2535929

NovoSeven as a universal haemostatic agent

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2535929

Use of factor IX complex in warfarin-related intracranial hemorrhage

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2535929

Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2535929

APACHE II: a severity of disease classification system

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2535929

Management of warfarin (coumarin) overdose

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2535929

Risk factors for intracranial hemorrhage in outpatients taking warfarin

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2535929

Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2535929

The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2535929

Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2535929

Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2535929

Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2535929

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2535929

Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2535929

Long-term anticoagulant therapy in cerebrovascular disease: does bleeding outweigh the benefit?

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2535929

A possible mechanism of action of activated factor VII independent of tissue factor

22 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16159073

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16159073

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Guidelines for the Management of Spontaneous Intracerebral Hemorrhage

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16159073

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1385/NCC:2:3:263

1 reference

Dimensions Publication ID

13 August 2017

0 references

1 reference

13 August 2017

PubMed publication ID

16159073

1 reference